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CytomegalovirusIn pediatric and adult patients after stem cell transplantation (SCT) disseminated infections caused by human
cytomegalovirus (HCMV) can cause life threatening diseases. For treatment, the three antivirals ganciclovir
(GCV), foscarnet (PFA) and cidofovir (CDV) are approved and most frequently used. Resistance to all of these
antiviral drugs may induce a severe problem in this patient cohort. Responsible for resistance phenomena are
mutations in the HCMV phosphotransferase-gene (UL97) and the polymerase-gene (UL54). Most frequently
mutations in theUL97-gene are associatedwith resistance to GCV. Resistance against all three drugs is associated
tomutations in the UL54-gene.Monitoring of drug resistance by genotyping ismostly done by PCR-based Sanger
sequencing. For phenotyping with cell culture the isolation of HCMV is a prerequisite. The development of
multidrug resistance with mutation in both genes is rare, but it is often associated with a fatal outcome. The
manifestation of multidrug resistance is mostly associated with combined UL97/UL54-mutations. Normally,
mutations in the UL97 gene occur initially followed by UL54 mutation after therapy switch. The appearance of
UL54-mutation alone without any detection of UL97-mutation is rare. Interestingly, in a number of patients
the UL97 mutation could be detected in speciﬁc compartments exclusively and not in blood.
© 2015 Göhring et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
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TheHumanCytomegalovirus (HCMV) belongs to the Betaherpesvirus
family and leads, after primary infection, to a lifelong latency. Underogy and Epidemiology of Viral
ny. Tel.: +49 7071 2980177.
n.de (K. Göhring).
. on behalf of the ResearchNetwork o
/4.0/).special condition such as immunosuppression, the virus can be
reactivated and may lead to severe diseases. The HCMV genome
comprised about 230 kb with more than 250 open reading frames.
Transplant recipients have a high risk to develop a primary infection
or recurrent infection with human cytomegalovirus (HCMV) [1]. The
incidence depends on different risk factors as serostatus, duration of
treatment and immunosuppressive regimen. Antiviral drugs for the
therapy of disseminated HCMV infection are ganciclovir (GCV),f Computational and Structural Biotechnology. This is an open access article under the
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UL54-gene which encodes for the viral DNA polymerase. GCV has
to be phosphorylated by the viral phosphotransferase UL97. Muta-
tions in both genes can lead to an antiviral resistance. Because GCV
is the drug of choice for primal therapy, most resistance mutations
can be detected in the UL97 gene. In some cases additional mutation
in the UL54 gene can be detected after a therapy switch to either PFA
or CDV.
The development ofmultidrug resistant HCMV infection and disease
with mutations in the UL97- and the UL54-gene after allogeneic hema-
topoietic cell transplantation (HCT) can be life-threatening. Therefore a
rapid and close meshed monitoring of HCMV infection and viral load
under therapy after HCT is mandatory [3–5].
Diagnosis of resistant HCMV infection is mostly performed by geno-
typic assays of UL97 and UL54 genes. A basic problem is the interpreta-
tion of unknown or rarely reported point mutations. To concern this,
Marker Transfer Analysis is needed and a web-based data base for
HCMV drug resistance mutations was established [6].
New compounds with different mechanism of action are under
investigation [7–9]. The clinical effectiveness ofMaribavir is still investi-
gated in clinical trials and is not commercially available up to now
[10–12]. This short review will focus on the development of drug- and
multidrug resistance and the characterization of newly detected
mutations.
2. The UL97 Open Reading Frame
The UL97 gene encodes for the viral phosphotransferase. Beside
many other targets like for example pUL44, pUL69 [13] or IFI16 [14], it
is responsible for the phosphorylation of GCV. The UL97-protein
contains several conserved subdomains with speciﬁc functions
(Fig. 1). The subdomain I is responsible for ATP binding, subdomains
II, III, VIB and VII are involved in the phosphate transfer and subdomain
IX is essential for substrate binding. Mutations in the UL97 gene might
cause resistance to GCV [13].(A)
(B)
Fig. 1. (A) Position of the UL54 and the UL97 open reading frame in the genome of HCMV strain
gene. Mutations can lead to resistance to GCV, CDV or PFA and can also cause multidrug resis
Mutations in the UL97 gene can cause resistance to GCV.3. The UL54 Open Reading Frame
The UL54 gene of HCMV encodes for the viral DNA polymerase. Like
a wide range of DNA polymerases, the UL54 protein has conserved
functional regions (Fig. 1). Mutations in the HCMV polymerase gene
might cause resistance to GCV, CDV and PFA and can also generate
multidrug resistance phenotypes [13].4. Risk Groups and Factors
Risk groups for the development of disseminated HCMVdiseases are
patients with impaired immune system including patients with AIDS,
transplant recipients, congenitally HCMV-infected premature infants
and patients with immune deﬁciency, but prevalence data are limited.
The risk to develop a resistant HCMV infection in transplant patients
depends on different factors such as serostatus, type of transplant
and the level of immunosuppression [7]. For the prevention of HCMV
disease in transplant patient, two different strategies are used.
Prophylactic treatment using valganciclovir seems to be a common
strategy in organ transplant recipients [1]. Patients after stem cell trans-
plantation have a high risk to develop a severe HCMV disease [13]. This
is due to a high immunosuppressive therapy and to long term donation
of antiviral drugs. Normally these patients received pre-emptive
therapy [15]. The development of a resistant HCMV infection can be
observed after prolonged drug exposure over weeks or months with
the greatest risk for CMV seronegative patients after solid organ
transplantation receiving an organ from a seropositive donor with a
frequency of 5–10% [16]. In kidney transplant recipients the incidence
increased up to 12.5% and seems to be still higher in lung transplant
recipients [13,17–19]. Besides antiviral potency, bioavailability and
effectiveness of drug delivery are important factors for the development
of antiviral drug resistance [13]. This is also of importance in the context
of the development of antiviral drug resistance in different
compartments.(C)
TB40E [50]. (B) UL54 open reading framewith conserved subdomains (black boxes) of the
tance. (C) UL97 open reading frame including the conserved subdomains (black boxes).
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Therapy against HCMV diseases is due to three antiviral drugs.
The nucleoside analogue ganciclovir (GCV) is used as gold-standard.
The L-valyl ester of ganciclovir valganciclovir (ValGCV) can be adminis-
trated orally and is rapidly absorbed and hydrolyzed to ganciclovir [7]. It
is phosphorylated by the viral UL97-gene product and cellular kinases
and is afterwards incorporated in the growing DNA-chain and leads to
elongation stop. Adverse effects of ValGCV and GCV are neutropenia
and teratogenic and hematotoxic effects [18]. Cidofovir (CDV), a
nucleotide analogue, is phosphorylated by cellular kinases and stops
also chain elongation, since viral DNA polymerase is the ﬁnal target
molecule. It has severe secondary effects like nephrotoxicity and
neutropenia which limits the clinical application. The pyrophosphate
analogue foscarnet (PFA) interacts directly with the viral polymerase
for the pyrophosphate binding site, encoded by the UL54 open reading
frame, and inhibits the enzyme reversible [20–22]. The treatment with
PFA showed many adverse effects like electrolyte abnormalities,
anemia and granulocytopenia that limit the clinical use of the drug
[18]. Mutations in the HCMV phosphotransferase-gene (UL97) and the
polymerase gene (UL54) are responsible for resistance to ganciclovir
(GCV), cidofovir (CDV) and foscarnet (PFA). Over 90% of all GCV-
resistant clinical isolates do have mutations in the UL97 gene [2,7].
Special mutations in conserved subdomains of the UL54-gene can
cause resistance to GCV, CDV and PFA as well as cross-resistance
between all three antiviral drugs. Resistance to Maribavir is mediated
by mutations in the UL97- and the UL27 gene [8,13,22].
6. Laboratory Diagnostics
6.1. Genotypic Assays
The gold standard and mostly used genotypic method for the detec-
tion of resistant HCMV strains is Sanger sequencing of PCR products
from the UL97 and the UL54 genes [13]. Different new techniques
have been established [23]. Deep sequencing methods allow the detec-
tion of minorities of mutations in a patient isolate mixture [24,25].
However, the importance of minor subpopulations in context of treat-
ment remains unclear [26].
Other methods for the detection of drug resistance associated muta-
tions are restriction fragment length polymorphism (RFLP) and real
time PCR assays. Both methods allow a detection of resistant mutations
in the UL97 gene. The RFLP is based on restriction endonuclease recog-
nition sites in PCR products of theUL97 gene.Mutations result in gain or
loss of these restriction sites and in comparison to a wildtype control,
detection of mutations can be performed by digest of the PCR product
followed by agarose gel electrophoresis. With different enzymes a
pattern of fragments could be compared. Other advantages are that
ampliﬁcation can be made directly from material of the patient; it is
fast, cost saving, easy to perform and mixtures of wildtype and mutant
strains can be detected. Nevertheless, the RFLP analysis is restricted to
known mutations that lead to a gain or loss of restriction sites. New
mutations cannot be detected using thismethod [27–32], and an appro-
priate assay for detection of gain or loss of a deﬁned point mutation has
to be available. The most important canonical UL97 mutations are
detectable via RFLP (recognition site), like M460V (NlaIII), M460I
(Mse I) [47], A591V (HaeIII), C592G (FseI) [90,91], A591V/C592G
(HaeIII/Fse I/Taq I) [47], A594V (Hin6I), L595S (Taq I), L595F (Mse
I) [29], C603W [91], and C607Y [71]. RFLP assays for HCMV UL54 have
no diagnostic value, since they are distributed over the whole gene.
Real-time PCR using melting curve analysis for the detection of
speciﬁc UL97-mutation is a very fast and sensitivemethod. It also allows
a semiquantitative detection of wildtype and mutant mixtures out of
patient material and a simultaneously detection of different mutations
in the same approach. Equally to RFLP analysis, the real time PCR
approaches can only detect known mutations. The assays cannotdistinguish between different mutations and polymorphisms near
knownmutations can inﬂuence themelting curve [33,34]. Nevertheless,
these assays are a good tool for a rapid screening of the most common
UL97-mutations out of patient materials.
6.2. Phenotypic Assays
The phenotypic characterization of isolates extracted from patient
materials is very time consuming for HCMV and has only restricted
use in routine diagnostics, since it is prerequisite to get a viral isolate.
Nevertheless if a viral isolate is available, it is possible to check beside
GCV the susceptibility also to PFA and cidofovir. However it remains
important in cases with unclear genotypic results or detecting of new
mutations.
Different types of Plaque reduction assays (PRAs) were described
which are based on the determination of a required drug concentra-
tion necessary to reduce viral growth in cell culture, the ID50 (inhib-
itory dose 50%) values which deﬁne the halfmaximal reduction of the
number of HCMV plaques resulting from in vitro culture without
anitiviral compound. Standardization of these PRAs is still a problem,
especially in context of deﬁnitions of cut-off levels for resistance,
which also depends on the availability of suitable therapy-naïve
wild-type virus strains. Nevertheless, these assays are necessary to
conﬁrm new mutations and to clarify unclear genotypic results
[35–38].
An interesting tool for the correlation of genotypic results to a
speciﬁc potentially resistant phenotype was published by Chevillotte
et al. [39]. Comparable to databases for HBV or HIV drug resistance,
the platform allows a correlation of Marker Transfer veriﬁed UL97-
and UL54 mutations to a correspondent phenotype.
7. Marker Transfer
Marker Transfer Analysis comprised the incorporation of a not
described UL97- or UL54- mutation in the wildtype background of
HCMV followed by o phenotypic characterization of the resulting
recombinant HCMV strain in comparison to the wildtype. The large
and complex genome of HCMVwas a huge problem in early time period
of antiviral testing. Using homologous recombination by cotransfection,
multiple segments of HCMV-DNA was cotransfected into HFF [29,40].
One segment contained the mutation which should be characterized;
the other segments were wildtype HCMV DNA. The resulting virus
had to be propagated and ﬁnally plaque puriﬁed. Recombination
events are normally very rare and cannot be controlled in cell culture.
Therefore the generation of HCMV mutant using this method was
time consuming and often not successful. Also the co-transfection of
cosmid clones was very hard to perform [41].
A milestone for the generation of recombinant HCMV mutants was
the development of HCMV as bacterial artiﬁcial chromosome (BAC).
Different methods for the reconstitution of HCMV-BAC mutants were
described [42–44]. BAC clones are very stable and the mutagenesis can
be performed in speciﬁc Escherichia coli strains where the recombina-
tion of HCMV BAC with a PCR product containing the unknown muta-
tion, can be controlled. The most effective one was published by
Tischer et al. [45,46] and allows the generation of HCMV mutants in
E.coliwithout any foreign sequences. The resulting BAC mutant DNA is
then transfected into HFF and after propagation, phenotypic character-
ization can be performed. The characterization of the recombinant
HCMV-BACs is normally done using PRA.
8. Multidrug Resistance
Multidrug resistance in patients under antiviral treatment of HCMV
diseases is described by different groups [3,4,39,48,49]. The appearance
of resistant phenotype against all available drugs often leads to a fatal
outcome.
Table 2
Resistancemutations in theUL54gene conﬁrmedbyMarker Transfer. Resistance ratios are
marked in bold numbers.
Mutation GCV ratio PFA ratio CDV ratio References
D301N 2.6 0.5 3 [74]
N408D 4.9 1.3 5.6 [41]
N408K 4.2 0.7 21 [75]
N408S 3.1 Nd 7.5 [92]
N410K 2.9 0.8 3 [74]
F412C 4.2 1.2 18 [76]
F412V 4.3 1.1 15.5 [41]
F412L 4.6 1.1× 9.4× [93]
F412S 5.3 0.8× 13× [93]
D413A 6.5 0.8 11 [77]
D413E 4.8 0.8 4.3 [74,91]
P488R 3.5 Nd 7.9 [93]
N495K 1.1 3.4 1.1 [77]
L501I 6 1.4 9.1 [41]
T503I 2.9 0.5 6.1 [74]
K513E 5 1.4 9.1 [41]
K513N 6 1.1 12.5 [78]
D515E 2.4 1.1 1.6 [73]
L516R 2.1 0.8 5.1 [74]
I521T 3.1 0.9 3.9 [79]
P522A 3 1 4.1 [79]
P522S 3.1 1.1 3.6 [41]
C539R 3.2 Nd 13.3 [93]
L545S 3.5 1.2 9.1 [41]
L545W 5.9 1.3× 6.3× [93]
Q578H 3.3 4.5 2.3 [93]
Q578L 1.9 3.0 0.8 [93]
D588E 1.3 2.3 1.1 [41,81]
D588N 3.8 3.2–9 2.7 [80]
T700A 0.9 4.7 1.5 [82]
V715M 1 5.5 1.1 [82]
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treatment span weeks or months. Normally therapy of a HCMV disease
with a positiveDNAemia inwhole blood or plasma startswith the dona-
tion of GCV as drug of choice. In most cases the viral load decreases.
Mutations in the UL97 gene can be observed shortly before a ﬁrst viral
peak value. After a therapy switch to either PFA or CDV the viral load
decreases again. After weeks of treatment, additional UL54 mutations
can be observed before the viral load increases again [48]. Isolated
UL54-mutations leading to a resistance phenotype are rarely reported.
Phenotypic assay normally conﬁrms and completes the genotypic
results. Newly detected mutations have to be conﬁrmed by Marker
Transfer Analysis. Also combination of different mutation In UL97-
and UL54 gene have to be investigated [48]. The mutations character-
ized up to now are illustrated in Tables 1 and 2.
9. Summary
The development of drug- or multidrug resistant HCMV infection in
patients after SCT might cause severe clinical problems. Mutations in
the UL97 can lead to resistance to GCV while mutations in the UL54
gene region can cause resistance to all three antiviral drugs GCV, CDV
and PFA. Since GCV is the ﬁrst choice for treatment, mutations in the
UL97 gene appearﬁrst followed by UL54mutations after therapy switch
resulting in a multidrug resistant phenotype.
There are limited reports about the development of multidrug
resistance in transplant recipients [3,4,39,48,49]. Multidrug resistant
HCMV infection can cause potential lethal HCMV disease. Close
monitoring of HCMV reactivation by PCR and to follow up the viral
load under therapy after HCT as well as after organ transplantation is
mandatory. The role of speciﬁc combinations of UL97- and UL54-Table 1
Resistance mutations in the UL97 gene conﬁrmed by Marker Transfer or recombinant
phenotype.
Mutation GCV ratio References
L405P 2.5 [51]
M460I 5 [37,52–54,18,55,56]
M460T 9.3 [51]
M460V 8.3 [18,28,31,37,54–60]
V466G 3.5 [61]
C518Y 12 [92]
H520Q 10 [28,31,37,54,58,61,46]
Del591–594 3–10 [28,31,40,54]
Del591–607 6.2 [54]
C592G 2.9 [18,55,57,59]
A594E 3.0 [51]
A594G 13.5 [18,65]
A594P Na [18,37,53,64]
A594T 2.7 [18,28,31,37,53–55]
A594V 8.3 [28,31,37,46,53–58]
L595F 15.7 [18,54–56]
L595S 9.2 [28,31,37,53–55,57–59,89]
L595W 5.1 [37,54,58]
L595del 13.3 [66]
Del595–603 8.4 [67]
E596G 2.3 [53,54]
E596Y 6.4 [73]
G598S Na [68]
K599T 5.3 [69]
L600del 1.9 [54]
T601del Nq [70]
Del601–603 11 [60]
C603R 3.6–8.3 [37,51,61]
C603S 1.9 [37,51]
C603W 8 [18,28,37,46,51,53–55,89]
C607F 1.9 [18,28,54]
C607Y 12.5 [18,37,54,71]
I610T 2.6 [73]
A613V 2.3 [72]
E756D 1.2 3.4 0.7 [74]
E756K 3.5 N8 2.2 [74,91]
E756Q 1.7 4.3 1 [83]
L776M 2.5 3.5 1 [84]
V781I 1–4 4–5.2 1.2 [41,80]
V787L 2.4 4.1 1 [83]
L802M 1.1–3.5 3.2–10.8 0.9–1.8 [41,76]
K805Q 1 0.18 2.2 [41]
A809V 2.6 6.3 1.7 [85]
V812L 2.5 2.9 3.2 [78]
T813S 2.5 4.9 2.7 [86]
T821I 4.5 21 1.9 [41]
A834P 5.4 6.4 3 [75]
T838A 1.8 2.4 0.8 [81]
G841A 3.2 4.3 2.6 [86]
Del981–982 8.3 3.6 2.8 [87]
A987G 5.3 1.2 11.3 [88]mutations as well as polymorphisms associated mutations have to be
further analyzed with regard to the clinical outcome and treatment
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